Literature DB >> 24572206

Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?

Dario Sorrentino1, Peter Nash, Monica Viladomiu, Raquel Hontecillas, Josep Bassaganya-Riera.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24572206     DOI： 10.1097/01.MIB.0000442680.47427.bf

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  10 in total

Review 1.  The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.

Authors:  Javier P Gisbert; Alicia C Marín; María Chaparro
Journal:  Am J Gastroenterol       Date:  2016-03-22       Impact factor: 10.864

Review 2.  Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease.

Authors:  Konstantinos Papamichael; Severine Vermeire
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

Review 3.  Update on the Medical Management of Crohn's Disease.

Authors:  Parakkal Deepak; David H Bruining
Journal:  Curr Gastroenterol Rep       Date:  2015-11

Review 4.  Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.

Authors:  N A Kennedy; B Warner; E L Johnston; L Flanders; P Hendy; N S Ding; R Harris; A S Fadra; C Basquill; C A Lamb; F L Cameron; C D Murray; M Parkes; I Gooding; T Ahmad; D R Gaya; S Mann; J O Lindsay; J Gordon; J Satsangi; A Hart; S McCartney; P Irving; C W Lees
Journal:  Aliment Pharmacol Ther       Date:  2016-02-19       Impact factor: 8.171

5.  Discontinuation of Scheduled Infliximab in Crohn's Patients With Clinical Remission: A Retrospective Single-Center Study.

Authors:  Huiqin Hu; Cheng Xiang; Chen Qiu; Zhao Chen; Silin Huang; Li Liang; Xinying Wang
Journal:  Gastroenterology Res       Date:  2017-04-19

Review 6.  Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies.

Authors:  Junjun Zhao; Qiliang Lu; Yang Liu; Zhan Shi; Linjun Hu; Zhi Zeng; Yifeng Tu; Zunqiang Xiao; Qiuran Xu
Journal:  J Immunol Res       Date:  2021-01-22       Impact factor: 4.818

7.  Optimising IBD patient selection for de-escalation of anti-TNF therapy to immunomodulator maintenance.

Authors:  Rachael Swann; Alan Boal; Seth Ian Squires; Carly Lamb; Laura Louise Clark; Selina Lamont; Graham Naismith
Journal:  Frontline Gastroenterol       Date:  2019-05-03

8.  Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.

Authors:  Dario Sorrentino; Marco Marino; Themistocles Dassopoulos; Dimitra Zarifi; Tiziana Del Bianco
Journal:  PLoS One       Date:  2015-12-15       Impact factor: 3.240

Review 9.  TH17 Cell and Epithelial Cell Crosstalk during Inflammatory Bowel Disease and Carcinogenesis.

Authors:  Jan Kempski; Leonie Brockmann; Nicola Gagliani; Samuel Huber
Journal:  Front Immunol       Date:  2017-10-25       Impact factor: 7.561

10.  The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study.

Authors:  Thomas Langford; Zehra Arkir; Anastasia Chalkidou; Kate Goddard; Lamprini Kaftantzi; Mark Samaan; Peter Irving
Journal:  JMIR Res Protoc       Date:  2018-10-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.